Log in

NASDAQ:ACIU - AC Immune Stock Price, Forecast & News

$8.41
+0.01 (+0.12 %)
(As of 02/23/2020 04:00 PM ET)
Today's Range
$8.18
Now: $8.41
$8.46
50-Day Range
$8.34
MA: $9.07
$9.89
52-Week Range
$4.24
Now: $8.41
$10.14
Volume171,924 shs
Average Volume162,591 shs
Market Capitalization$568.18 million
P/E Ratio12.01
Dividend YieldN/A
Beta0.34
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACIU
CUSIPN/A
Phone41-21-345-9121

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.36 million
Book Value$2.76 per share

Profitability

Net Income$-52,090,000.00

Miscellaneous

Employees92
Market Cap$568.18 million
Next Earnings Date3/19/2020 (Estimated)
OptionableNot Optionable

Receive ACIU News and Ratings via Email

Sign-up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter.


AC Immune (NASDAQ:ACIU) Frequently Asked Questions

What is AC Immune's stock symbol?

AC Immune trades on the NASDAQ under the ticker symbol "ACIU."

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) issued its quarterly earnings data on Wednesday, November, 13th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.17 by $0.08. The firm earned $33.90 million during the quarter, compared to the consensus estimate of $31.50 million. AC Immune had a net margin of 45.19% and a return on equity of 19.18%. View AC Immune's Earnings History.

When is AC Immune's next earnings date?

AC Immune is scheduled to release their next quarterly earnings announcement on Thursday, March 19th 2020. View Earnings Estimates for AC Immune.

What price target have analysts set for ACIU?

1 analysts have issued 12 month price targets for AC Immune's stock. Their forecasts range from $11.00 to $11.00. On average, they expect AC Immune's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 30.8% from the stock's current price. View Analyst Price Targets for AC Immune.

What is the consensus analysts' recommendation for AC Immune?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AC Immune.

Has AC Immune been receiving favorable news coverage?

News headlines about ACIU stock have been trending somewhat negative on Sunday, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. AC Immune earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for AC Immune.

Are investors shorting AC Immune?

AC Immune saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 452,700 shares, an increase of 11.4% from the January 15th total of 406,200 shares. Based on an average trading volume of 133,400 shares, the days-to-cover ratio is currently 3.4 days. Approximately 1.4% of the shares of the stock are sold short. View AC Immune's Current Options Chain.

Who are some of AC Immune's key competitors?

What other stocks do shareholders of AC Immune own?

Who are AC Immune's key executives?

AC Immune's management team includes the folowing people:
  • Dr. Andrea Pfeifer, Co-Founder, CEO & Director (Age 61)
  • Mr. Joerg Hornstein, Chief Financial Officer (Age 41)
  • Mr. Piergiorgio Donati, Head of Technical Operations & Program Management (Age 48)
  • Dr. Marie Kosco-Vilbois, Chief Scientific Officer (Age 61)
  • Mr. Jean-Fabien Monin, Chief Admin. Officer (Age 48)

When did AC Immune IPO?

(ACIU) raised $55 million in an IPO on Friday, September 23rd 2016. The company issued 4,600,000 shares at $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Who are AC Immune's major shareholders?

AC Immune's stock is owned by many different of institutional and retail investors. Top institutional investors include BVF Inc. IL (16.79%), Renaissance Technologies LLC (0.72%), Acadian Asset Management LLC (0.48%), Marshall Wace LLP (0.20%), FMR LLC (0.10%) and Alpine Woods Capital Investors LLC (0.06%).

Which institutional investors are selling AC Immune stock?

ACIU stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Geode Capital Management LLC, Marshall Wace North America L.P., Tower Research Capital LLC TRC and ProShare Advisors LLC.

Which institutional investors are buying AC Immune stock?

ACIU stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Renaissance Technologies LLC, Marshall Wace LLP, BVF Inc. IL, Alpine Woods Capital Investors LLC, Oxford Asset Management LLP, Trexquant Investment LP and Spark Investment Management LLC.

How do I buy shares of AC Immune?

Shares of ACIU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AC Immune's stock price today?

One share of ACIU stock can currently be purchased for approximately $8.41.

How big of a company is AC Immune?

AC Immune has a market capitalization of $568.18 million and generates $7.36 million in revenue each year. The company earns $-52,090,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. AC Immune employs 92 workers across the globe.View Additional Information About AC Immune.

What is AC Immune's official website?

The official website for AC Immune is http://www.acimmune.com/.

How can I contact AC Immune?

AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The company can be reached via phone at 41-21-345-9121 or via email at [email protected]


MarketBeat Community Rating for AC Immune (NASDAQ ACIU)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  222 (Vote Underperform)
Total Votes:  442
MarketBeat's community ratings are surveys of what our community members think about AC Immune and other stocks. Vote "Outperform" if you believe ACIU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACIU will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel